Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several core dosing/indication elements align with the provided label excerpts, but multiple safety and dose-adjustment claims are not supported by the excerpted label text (e.g., mechanism detail and rationale for more frequent dosing). Also, the “more frequent dosing” statements are partially inconsistent with label language (label describes increasing dosage to 300 mg every 2 weeks only for inadequate response in certain indications, not generalized “breakthrough symptoms”).
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported for indicated conditions (label excerpts include plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis), but the “biologic” and “autoimmune diseases” framing is not explicitly stated in the provided excerpts.
For psoriasis, the recommended dose of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by maintenance doses every 4 weeks.
Label excerpt: “recommended dosage in adults with PsO is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.”
For ankylosing spondylitis, the recommended dose of Cosentyx is 150 mg administered subcutaneously at weeks 0, 1, 2, and 3, followed by maintenance doses every 4 weeks.
Label excerpt for AS with a loading dosage specifies 150 mg at Weeks 0,1,2,3,4 and every 4 weeks thereafter (note: AI claim omits Week 4 in the loading schedule).
Unsupported Statements
Cosentyx works by blocking the action of interleukin-17A.
No mechanism statement (IL-17A) appears in the provided label excerpts.
For psoriatic arthritis, the recommended dose of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by maintenance doses every 4 weeks.
Provided label excerpt for adult PsA subcutaneous loading dose states 150 mg at Weeks 0,1,2,3,4 and every 4 weeks thereafter, with consideration to increase to 300 mg every 4 weeks if active PsA continues. The AI claim states 300 mg as the recommended dose for the initial schedule.
The typical dosing schedule for Cosentyx is every 4 weeks for psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Label excerpts indicate every-4-weeks maintenance for the stated loading regimens, but do not support a blanket “typical dosing schedule” across all patients/indications without qualification (and the AI later adds more-frequent dosing).
More frequent dosing of Cosentyx (more than once a month) may be needed in some situations.
While the label includes specific instructions for dose increase in certain contexts (e.g., increasing to 300 mg every 2 weeks for HS, and considering increasing dose for active PsA/AS), the provided excerpts do not support a generalized statement that more frequent dosing may be needed “in some situations” across indications.
Taking Cosentyx more frequently than once a month should be done under the guidance of a healthcare provider.
The excerpted label does not explicitly state this guidance for dose-frequency changes.
More frequent dosing of Cosentyx may be used for inadequate response to the standard dosing schedule.
Dose increase for inadequate/continued disease activity is described for PsA and AS (“consider increasing the dosage to 300 mg every 4 weeks”) but the excerpted text does not describe more-frequent (e.g., >q4w) dosing for inadequate response for those indications. For HS, the excerpt describes increasing to 300 mg every 2 weeks if an adult patient does not adequately respond; however the AI statement is generalized across indications.
More frequent dosing of Cosentyx may be used to manage breakthrough symptoms.
“Breakthrough symptoms” is not mentioned in the provided label excerpts.
More frequent dosing of Cosentyx may involve careful monitoring of the patient's response.
The excerpted label does not explicitly link dose-frequency increases to “careful monitoring of response” as a stated instruction.
More frequent dosing of Cosentyx may increase the risk of injection site reactions.
The provided label excerpts do not state an association between dose frequency and injection site reactions.
More frequent dosing of Cosentyx may increase the risk of adverse events such as headaches, fatigue, and nausea.
The provided label excerpts do not list these adverse events nor state that more frequent dosing increases their risk.
More frequent dosing of Cosentyx may increase immunogenicity, potentially leading to development of antibodies against the medication.
No immunogenicity/antibody development statement appears in the provided excerpts.
More frequent dosing of Cosentyx may increase cost and logistical challenges.
No cost/logistics statements appear in the provided label excerpts.
Patients with a history of injection site reactions should discuss their medical history with their healthcare provider before starting Cosentyx.
The provided label excerpts do not include this specific counseling statement regarding injection site reactions history.
Contradictions
High
AI Statement
For psoriatic arthritis, the recommended dose of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by maintenance doses every 4 weeks.
Label Reference
2.4 Recommended Subcutaneous Dosage in Adults with PsA: “with a loading dosage is 150 mg at Weeks 0,1,2,3,4 and every 4 weeks thereafter… If a patient continues to have active PsA, consider increasing the dosage to 300 mg… every 4 weeks.”
Low
AI Statement
For ankylosing spondylitis, the recommended dose of Cosentyx is 150 mg administered subcutaneously at weeks 0, 1, 2, and 3, followed by maintenance doses every 4 weeks.
Label Reference
2.6 Recommended Subcutaneous Dosage in Adults with AS: “With a loading dosage is 150 mg at Weeks 0,1,2,3,4 and every 4 weeks thereafter…”
Important Omissions
For psoriatic arthritis subcutaneous dosing, label excerpt specifies 150 mg loading (not 300 mg) with consideration to increase to 300 mg every 4 weeks if active disease continues.
Importance:
High
For ankylosing spondylitis subcutaneous loading schedule includes Week 4 (Weeks 0,1,2,3,4) before every-4-weeks maintenance.
Importance:
Moderate
Label excerpt includes specific pre-treatment evaluations (TB) and immunization considerations (avoid live vaccines) that were not addressed in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Primary risk from inaccurate dosing statements (notably PsA initial loading dose) and generalized, unsupported dose-frequency/safety/risk claims not tied to label-specific dose adjustment instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Psoriatic arthritis subcutaneous loading dose is misstated (300 mg instead of 150 mg with consideration to increase), and several generalized more-frequent dosing safety rationales are unsupported by the provided label excerpts.
Suggested Improvement
Align dosing to the label excerpts for each indication (PsA starting 150 mg loading; include Week 4 for AS loading). Replace generalized “more frequent dosing” and safety assertions with indication- and label-specific dose adjustment language (e.g., consider increase to 300 mg every 4 weeks for persistent PsA/AS, and 300 mg every 2 weeks for HS inadequate response per the excerpt). Avoid adding mechanism, immunogenicity, and adverse-event/risk claims unless present in the label excerpts provided.